Form 8-K AtriCure, Inc. For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
November 4, 2021 6:44 AM EDTNeedham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $92.00 (from $90.00) while maintaining a Buy rating.
The analyst commented, "ATRC's 3Q21 revenue, EBITDA, and EPS all beat consensus. While it has only been 6 months since EPi-Sense's FDA... More
